Abstract
85 Assessing tolerability and toxicity of adjuvant Osimertinib following tumour resection of early-stage EGFR-mutated non-small cell lung cancer through real-world data
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have